O	0	10	Evaluation
O	11	13	of
B-intervention	14	22	axillary
I-intervention	23	30	reverse
I-intervention	31	38	mapping
I-intervention	39	40	(
I-intervention	40	43	ARM
I-intervention	43	44	)
O	45	47	in
O	48	58	clinically
O	59	67	axillary
O	68	72	node
O	73	81	negative
O	82	88	breast
O	89	95	cancer
O	96	104	patients
O	105	106	-
O	107	117	Randomised
O	118	128	controlled
O	129	134	trial
O	134	135	.

O	136	144	Axillary
O	145	150	lymph
O	151	155	node
O	156	166	dissection
O	167	168	(
O	168	172	ALND
O	172	173	)
O	174	176	is
O	177	179	an
O	180	189	important
O	190	199	procedure
O	200	203	for
O	204	211	control
O	212	214	of
O	215	223	axillary
O	224	229	nodal
O	230	240	metastasis
O	241	243	in
O	244	250	breast
O	251	257	cancer
O	258	266	patients
O	266	267	.

O	268	278	Lymphedema
O	278	279	,
O	280	291	restriction
O	292	294	of
O	295	303	shoulder
O	304	312	movement
O	313	316	and
O	317	325	axillary
O	326	331	nodal
O	332	342	recurrence
O	343	346	are
O	347	350	the
O	351	355	most
O	356	365	disabling
O	366	379	complications
O	380	382	of
O	383	386	the
O	387	396	procedure
O	396	397	.

O	398	406	Axillary
O	407	414	reverse
O	415	422	mapping
O	423	424	(
O	424	427	ARM
O	427	428	)
O	429	438	procedure
O	439	442	for
O	443	446	arm
O	447	452	lymph
O	453	457	node
O	458	472	identification
O	473	480	emerged
O	481	483	as
O	484	485	a
O	486	490	step
O	491	494	for
O	495	500	their
O	501	513	preservation
O	514	520	during
O	521	525	ALND
O	525	526	.

O	527	531	Here
O	532	534	we
O	535	538	are
O	539	546	testing
O	547	550	the
O	551	557	effect
O	558	560	of
O	561	564	ARM
O	565	567	on
O	568	578	lymphedema
O	579	590	development
O	591	594	and
O	595	602	whether
O	603	605	it
O	606	617	compromises
O	618	629	oncological
O	630	636	safety
O	637	639	in
O	640	645	early
O	646	652	breast
O	653	659	cancer
O	660	668	patients
O	668	669	.

B-total-participants	670	672	98
B-eligibility	673	683	clinically
I-eligibility	684	688	node
I-eligibility	689	693	free
I-eligibility	694	700	breast
I-eligibility	701	707	cancer
I-eligibility	708	714	female
I-eligibility	715	723	patients
I-eligibility	724	734	undergoing
I-eligibility	735	745	completion
I-eligibility	746	750	ALND
I-eligibility	751	756	after
I-eligibility	757	765	positive
I-eligibility	766	774	sentinel
I-eligibility	775	780	lymph
I-eligibility	781	785	node
I-eligibility	786	792	biopsy
O	793	797	were
O	798	807	recruited
O	808	810	in
O	811	814	the
O	815	820	study
O	820	821	.

O	822	826	They
O	827	831	were
O	832	835	put
O	836	840	into
O	841	846	group
O	847	848	A
O	849	850	(
B-intervention-participants	850	852	49
O	853	861	patients
O	862	866	with
O	867	870	ARM
O	871	872	+
O	873	875	ve
O	876	888	preservation
O	889	893	ALND
O	893	894	)
O	895	898	and
O	899	904	group
O	905	906	B
O	907	908	(
B-control-participants	908	910	49
O	911	919	patients
O	920	922	in
O	923	926	the
B-control	927	939	conventional
I-control	940	944	ALND
O	945	950	group
O	950	951	)
O	951	952	.

O	953	956	ARM
O	957	966	procedure
O	967	970	was
O	971	980	performed
O	981	983	in
O	984	988	both
O	989	995	groups
O	995	996	,
O	997	1000	ARM
O	1001	1009	positive
O	1010	1015	nodes
O	1016	1020	were
O	1021	1030	preserved
O	1031	1033	in
O	1034	1039	group
O	1040	1041	A
O	1041	1042	,
O	1043	1049	marked
O	1050	1053	and
O	1054	1059	taken
O	1060	1063	out
O	1064	1068	with
O	1069	1074	other
O	1075	1083	axillary
O	1084	1086	LN
O	1087	1089	in
O	1090	1095	group
O	1096	1097	B
O	1097	1098	.

O	1099	1102	The
O	1103	1110	outcome
O	1111	1114	was
B-outcome-Measure	1115	1129	histopathology
I-outcome-Measure	1130	1132	of
I-outcome-Measure	1133	1136	ARM
I-outcome-Measure	1137	1138	+
I-outcome-Measure	1139	1141	ve
I-outcome-Measure	1142	1144	LN
O	1144	1145	,
B-outcome-Measure	1146	1157	development
I-outcome-Measure	1158	1160	of
I-outcome-Measure	1161	1164	arm
I-outcome-Measure	1165	1175	lymphedema
O	1175	1176	,
O	1177	1180	and
B-outcome-Measure	1181	1192	restriction
I-outcome-Measure	1193	1195	of
I-outcome-Measure	1196	1204	shoulder
I-outcome-Measure	1205	1213	movement
O	1214	1216	on
O	1217	1223	follow
O	1223	1224	-
O	1224	1226	up
O	1226	1227	.

B-outcome	1228	1231	ARM
I-outcome	1232	1235	was
I-outcome	1236	1244	positive
O	1245	1247	in
B-iv-bin-abs	1248	1250	46
O	1251	1259	patients
O	1260	1261	(
B-iv-bin-percent	1261	1263	93
I-iv-bin-percent	1263	1264	.
I-iv-bin-percent	1264	1265	8
I-iv-bin-percent	1265	1266	%
O	1266	1267	)
O	1268	1270	in
O	1271	1276	group
O	1277	1278	A
O	1279	1282	and
B-cv-bin-abs	1283	1285	43
O	1286	1294	patients
O	1295	1296	(
B-cv-bin-percent	1296	1298	87
I-cv-bin-percent	1298	1299	.
I-cv-bin-percent	1299	1300	8
I-cv-bin-percent	1300	1301	%
O	1301	1302	)
O	1303	1305	in
O	1306	1311	group
O	1312	1313	B
O	1313	1314	,
O	1315	1318	ARM
O	1319	1320	+
O	1321	1323	ve
O	1324	1326	LN
O	1327	1335	revealed
B-outcome	1336	1344	positive
I-outcome	1345	1355	metastasis
O	1356	1360	only
O	1361	1363	in
B-cv-bin-abs	1364	1365	1
O	1366	1373	patient
O	1374	1375	(
B-cv-bin-percent	1375	1376	2
I-cv-bin-percent	1376	1377	.
I-cv-bin-percent	1377	1378	3
I-cv-bin-percent	1378	1379	%
O	1379	1380	)
O	1381	1383	in
O	1384	1389	group
O	1390	1391	B
O	1391	1392	.

B-outcome	1393	1403	Lymphedema
O	1404	1413	developed
O	1414	1416	in
B-iv-bin-abs	1417	1418	3
O	1419	1420	(
B-iv-bin-percent	1420	1421	6
I-iv-bin-percent	1421	1422	.
I-iv-bin-percent	1422	1423	5
I-iv-bin-percent	1423	1424	%
O	1425	1433	patients
O	1434	1436	in
O	1437	1442	group
O	1443	1444	A
O	1445	1448	and
B-cv-bin-abs	1449	1450	9
O	1451	1459	patients
O	1460	1461	(
B-cv-bin-percent	1461	1463	20
I-cv-bin-percent	1463	1464	.
I-cv-bin-percent	1464	1465	9
I-cv-bin-percent	1465	1466	%
O	1466	1467	)
O	1468	1470	in
O	1471	1476	group
O	1477	1478	B
O	1478	1479	.

O	1480	1491	Restriction
O	1492	1494	of
O	1495	1503	shoulder
O	1504	1512	movement
O	1513	1519	showed
O	1520	1521	a
O	1522	1525	non
O	1525	1526	-
O	1526	1537	significant
O	1538	1548	difference
O	1549	1556	between
O	1557	1560	the
O	1561	1564	two
O	1565	1571	groups
O	1571	1572	.

O	1573	1581	Axillary
O	1582	1589	reverse
O	1590	1597	mapping
O	1598	1601	and
O	1602	1614	preservation
O	1615	1617	of
O	1618	1621	arm
O	1622	1632	lymphatics
O	1633	1639	helped
O	1640	1642	to
O	1643	1651	decrease
O	1652	1655	the
O	1656	1666	lymphedema
O	1667	1671	rate
O	1672	1679	without
O	1680	1692	compromising
O	1693	1704	oncological
O	1705	1711	safety
O	1712	1714	in
O	1715	1720	early
O	1721	1727	breast
O	1728	1734	cancer
O	1734	1735	.
